Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Kyowa Kirin to Acquire ProStrakan for ￡292 Mil.
February 28, 2011
- Light Ahead for Japanese Bioventures: Mr Yamazaki of IRI
February 28, 2011
- Aloxi Gains Top Share in Antiemetic Market in Just 8 Months: Otsuka
February 28, 2011
- Daiichi Sankyo Acquires US Packaging, Manufacturing Facility
February 28, 2011
- Takeda Ties Up with Covance, Quintiles to Accelerate Development
February 28, 2011
- Sanofi-aventis to Acquire Genzyme for US$20.1 Bil.
February 28, 2011
- FUJIFILM to Develop Comprehensive Healthcare Business
February 28, 2011
- Sales Up 9.1% in Japan: sanofi-aventis
February 28, 2011
- Need to Omit Clinical Trials Pointed Out to Encourage Manufacturing of Mo-99 in Japan
February 28, 2011
- MTPC Voluntarily Withdraws Its Membership from JPMA
February 28, 2011
- Edoxaban Recommended for Approval for VTE
February 28, 2011
- Takeda to Enhance Research Collaboration with Third Parties
February 28, 2011
- Escitalopram to Prop Up Business of Struggling Mochida
February 28, 2011
- Abilify Approved for Maintenance Adjuvant Therapy for Bipolar I Disorder in US
February 28, 2011
- GSK Starts Multinational PIII Study for DMD
February 28, 2011
- Pfizer to Stress Significance of Combining CCB, Statin in One Drug
February 28, 2011
- Increasing Number of Trials Conducted on Concurrent Use of Oral Hypoglycemic Agents
February 28, 2011
- Mylan Aims to Become Top-3 Generic Company in Japan in 5 Years
February 28, 2011
- Takeda to Voluntarily Recall Dasen
February 28, 2011
- Lixisenatide Not Inferior to Exenatide in PIII: sanofi-aventis
February 28, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…